SGLT1

1 paper

Animals1

Funding

2 grants since 2024

National Institute of Diabetes and Digestive and Kidney DiseasesUS$3.5m

Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report
National Institute of Diabetes and Digestive and Kidney DiseasesHealthPartners InstituteUS$2.4m2025–2028
Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease
National Institute of Diabetes and Digestive and Kidney DiseasesBoston Medical CenterUS$372.5k2023–2028

Latest

2 in 12 months

Handbook of Experimental Pharmacology13 Sep

Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals

ReviewSGLT2 inhibitors

Pharmaceuticals27 Feb

SGLT1 and SGLT2 Modulation in Antidiabetic Therapy-Comparative Insights into Gliflozins and Natural Compounds Resveratrol and Viniferin

ReviewResveratrol

Molecular Biology Reports3 Oct

Combined nicotinamide riboside and magnesium-l-theanine protects against chronic stress-induced gut-liver injury by modulating NAD⁺ and metabolic pathways

Experiments in animalsInterventions

International Journal of Molecular Sciences19 Jul

Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland

ReviewMechanisms

Cardiovascular Diabetology18 Feb

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Experiments in ratsEmpagliflozin